International Stem Cell (ISCO) Change in Account Payables (2010 - 2025)
International Stem Cell (ISCO) posted quarterly Change in Account Payables of -$97000.0 for Q4 2025, up 28.15% year-over-year from -$75693.6 in Q4 2024, and up 26.52% quarter-over-quarter from -$132000.0 in Q3 2025.
International Stem Cell (ISCO) Change in Account Payables (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Change in Account Payables for 16 consecutive years, with -$97000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables rose 28.15% year-over-year to -$97000.0; the TTM figure through Dec 2025 stood at -$18000.0 (up 89.89% YoY), while the FY2025 annual figure was -$18000.0, up 89.89% from the prior year.
- Change in Account Payables grew to -$97000.0 in Q4 2025 per ISCO's latest filing, from -$132000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $271000.0 in Q1 2025 and bottomed at -$161000.0 in Q2 2022.
- Historically, Change in Account Payables has averaged -$9600.0 across 5 years, with a median of -$35500.0 in 2021.
- On a YoY basis, Change in Account Payables climbed as much as 6875.0% in 2025 and fell as far as 452.94% in 2025.
- International Stem Cell's Change in Account Payables stood at -$103000.0 in 2021, then surged by 45.63% to -$56000.0 in 2022, then surged by 208.93% to $61000.0 in 2023, then sank by 321.31% to -$135000.0 in 2024, then climbed by 28.15% to -$97000.0 in 2025.
- Business Quant data shows ISCO's Change in Account Payables at -$97000.0 in Q4 2025, -$132000.0 in Q3 2025, and -$60000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -97,000.00 |
| Dec 31, 2025 | -97,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Jun 30, 2025 | -60,000.00 |
| Jun 30, 2025 | -60,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Dec 31, 2024 | -135,000.00 |
| Dec 31, 2024 | -135,000.00 |
| Sep 30, 2024 | -56,000.00 |
| Sep 30, 2024 | -56,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Sep 30, 2023 | -28,000.00 |